Comparative Study Between Free Disease Interval of Modified Radical Mastectomy Versus Conservative Breast Surgery in Patients with Triple-Negative Breast Cancer
DOI:
https://doi.org/10.63682/jns.v14i9S.3502Keywords:
Mastectomy, Conservative Breast Surgery, Triple Negative Breast CancerAbstract
Background: Breast cancer is a significant concern in modern research due to its mortality and associated psychological aspects. In recent years, breast conservation surgery (BCS) and modified radical mastectomy (MRM) have been widely used in the treatment of early‐stage breast cancer. This study aims to compare the free disease interval of modified radical mastectomy (MRM) versus conservative breast surgery (Lumpectomy) in patients with triple-negative breast cancer stage I and stage II. Methods: In this retrospective-based record comparative study, 100 triple negative (invasive ductal carcinoma confirmed through histopathology) breast cancer females' stage I and stage II were enrolled, the study was conducted at 6 October University Hospital. This study compares free disease interval (3-5 years) of modified radical mastectomy and conservative breast surgery. The study record was over a period from 2015 to 2022.
Results: There was a significant positive correlation between age and metastatic patients (r = 0.329; P <0.010*). There was a significant positive correlation between metastatic patients and grade II, III & IV (r = 0.777, P <0.0001; r = 0.433, P <0.0001). There was a significant positive correlation between metastatic patients and stage Tmic/ T1a/ T1b, T1c, and T2 (r = 0.624; P <0.010*; r = 0.517; p <0.0001; r = 0.494, p <0.0001). There was a significant positive correlation between metastatic patients and lymph nodes N0 and N1 (r = 0.497; P <0.010*; r = 0.195, p <0.044*).
Conclusion: modified radical mastectomy and conservative breast surgery in triple-negative breast cancer female patients, both techniques represent successful rates, however; conservative breast surgery had a higher successful rate than modified radical mastectomy.
Downloads
References
Alaggio, R., Amador-Ortiz, C., Anagnostopoulos, I., ett al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022; 36(7), 1720–1748.
Kim, Y. S., Ryu, D. W., & Lee, C. H. (2016). Comparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients. Kosin Medical Journal, 31(1), 19–29.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast Cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368.
He MY, Rancoule C, Rehailia-Blanchard A, Espenel S, Trone JC, Bernichon E, et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96–101.
Guo, L., Xie, G., Wang, R. et al. Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?. BMC Cancer, 2021; 21, 717
Gammal, E. R. E., Abdulmohaymen, A. M., & Abdulmutaleb, B. a. M. M. (2019b). Comparative Study between Conservative Breast Surgery and Modified Radical Mastectomy in Triple Negative Cases. The Egyptian Journal of Hospital Medicine, 76(6), 4269–4273.
Houshyari, M., Rakhsha, A., Khademi, M., & Kashi, A. S. Y. (2019). A comparative matched study of Breast-Conserving therapy and modified radical mastectomy in Iranian women. International Journal of Cancer Management, 13(4).
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–37
Chen SS, Tang SC, Li K, Wu J, Li X, Ren H, et al. Predicting the survival of triple-negative breast Cancer in different stages: a SEER population based research referring to Clinicopathological factors. Cancer Investig. 2020:1–10
Luo J, Kroenke CH, Hendryx M, Shadyab AH, Liu N, Chen X, et al. Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women. Breast Cancer Res Treat. 2021.
Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. Racial/ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast Cancer. Cancer Res. 2021;81(4):1163–70.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
